{"abstract": "In taking its offer directly to Genzyme stockholders, Sanofi held to the $69-a-share price it has floated for months.", "web_url": "https://www.nytimes.com/2010/10/05/business/global/05drug.html", "snippet": "In taking its offer directly to Genzyme stockholders, Sanofi held to the $69-a-share price it has floated for months.", "lead_paragraph": "Sanofi-Aventis of France took its $18.5 billion takeover bid for Genzyme hostile on Monday, going directly to Genzyme\u2019s shareholders in an effort to advance deal negotiations.", "print_section": "B", "print_page": "8", "source": "The New York Times", "multimedia": [], "headline": {"main": "Sanofi Bid for Genzyme Turns Hostile, and No Sweeter", "kicker": null, "content_kicker": null, "print_headline": "Sanofi Bid for Genzyme Turns Hostile, and No Sweeter", "name": null, "seo": null, "sub": null}, "keywords": [{"name": "subject", "value": "Mergers, Acquisitions and Divestitures", "rank": 1, "major": "N"}, {"name": "organizations", "value": "Sanofi-Aventis SA", "rank": 2, "major": "N"}, {"name": "organizations", "value": "Genzyme Corp", "rank": 3, "major": "N"}], "pub_date": "2010-10-04T22:02:05+0000", "document_type": "article", "news_desk": "Business", "section_name": "Business Day", "subsection_name": "Global Business", "byline": {"original": "By Michael J. de la Merced and Thomas Kaplan", "person": [{"firstname": "Michael", "middlename": "J.", "lastname": "de la Merced", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}, {"firstname": "Thomas", "middlename": null, "lastname": "Kaplan", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 2}], "organization": null}, "type_of_material": "News", "_id": "nyt://article/c5ad9652-182a-5992-b98f-68cedb0b487b", "word_count": 556, "uri": "nyt://article/c5ad9652-182a-5992-b98f-68cedb0b487b"}